Shares of Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) dropped 1.1% on Tuesday . The stock traded as low as $2.17 and last traded at $2.17. Approximately 6,250 shares were traded during trading, a decline of 70% from the average daily volume of 20,531 shares. The stock had previously closed at $2.20.
Medexus Pharmaceuticals Stock Performance
The company has a fifty day simple moving average of $2.10 and a two-hundred day simple moving average of $2.01.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Read More
- Five stocks we like better than Medexus Pharmaceuticals
- How to Buy Gold Stock and Invest in Gold
- Is It Time to Trim Your Positions in These 2 AI Stocks?
- When to Sell a Stock for Profit or Loss
- These 3 Tech Stocks Just Supercharged Their Buybacks
- How to find penny stocks to invest and trade
- 3 Dividend Stocks to Hold Through Market Volatility This Fall
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
